AFFiRiS AG logo

AFFiRiS AG

Novel disease-modifying therapies for neurodegenerative diseases. From brains for brains. From us for you.

2 employees · est. 2003 · Wien, Austria

VS
Passage Bio logo

Passage Bio

Our mission is to improve the lives of patients with neurodegenerative diseases

43 employees · est. 2017 · Philadelphia, United States

AFFiRiS AG is the older company (2003 vs 2017); Passage Bio is the larger of the two.

Side-by-Side Comparison

AFFiRiS AG Passage Bio
Founded
2003 older 2017
Headquarters
Wien, Austria Philadelphia, United States
Employees
2 43 larger
Industry
Biotechnology, Pharmaceutical Biotechnology, Health Care, Health and Wellness
Funding Stage
Unknown Post Ipo Equity
Total Funding
$47.00M $379.50M
Funding Rounds
4 3
Services
Not tracked yet Development of genetic medicines, Clinical trials for CNS disorders, Gene therapy solutions
Target Customers
Not tracked yet Patients with neurodegenerative diseases, Healthcare professionals specializing in CNS disorders, Biotech and pharmaceutical investors
Taxonomy
Immunotherapy, Neurodegenerative Diseases, Parkinson's Disease, Alzheimer's Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Huntington's Disease, Clinical-stage Biotechnology, SAIT, AFFITOME Technology, Peptide Vaccines, Vienna, Austria, Clinical Trials, Monoclonal Antibody Neurodegenerative Diseases, Genetic Medicines, Clinical Stage, One-time Therapies, Lysosomal Function Restoration, Progranulin Elevation, AAV-delivered Therapeutics, Monogenic CNS Diseases, Gene Therapy, Frontotemporal Dementia, Research Collaboration, Preclinical Work, Clinical Development, Regulatory Affairs, Patient Advocacy Outreach
Website
affiris.com passagebio.com
AFFiRiS AG logo

About AFFiRiS AG

AFFiRiS AG is a clinical-stage biotechnology company based in Austria, founded in 2003. The company's slogan, "Novel disease-modifying therapies for neurodegenerative diseases. From brains for brains. From us for you," encapsulates their mission to challenge established treatment options for neurode...

Passage Bio logo

About Passage Bio

Passage Bio, founded in 2017 and headquartered in the United States, is a clinical stage genetic medicines company dedicated to improving the lives of patients with neurodegenerative diseases. The company operates within the Biotechnology, Health Care, and Health and Wellness industries. Their miss...

Be first to know when either one moves

Funding rounds, hiring surges, leadership changes and stack switches at AFFiRiS AG and Passage Bio — tracked continuously, sent the day they land.

Watch both — free

Funding, hiring, leadership and stack changes at AFFiRiS AG and Passage Bio — by email.

Frequently Asked Questions

AFFiRiS AG — Novel disease-modifying therapies for neurodegenerative diseases. From brains for brains. From us for you.. Passage Bio — Our mission is to improve the lives of patients with neurodegenerative diseases. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
AFFiRiS AG has raised $47.00M while Passage Bio has raised $379.50M.
AFFiRiS AG and Passage Bio operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare AFFiRiS AG with someone else

Start typing a company name or domain.

One analytics cookie (Google Analytics). Cookie Policy